CIK: 0001910264 · Show all filings
Period: Q1 2025 (← Previous) (Next →)
Filing Date: May 13, 2025
Total Value ($000): $389,283 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ACLX | Arcellx, Inc. | 2,346,630 | $153,939 | 39.5% | $16.72 | +305.2% | Common Stock | 03940C100 |
| SPRY | ARS Pharmaceuticals, Inc. | 4,012,903 | $50,482 | 13.0% | $6.79 | +77.3% | Common Stock | 82835W108 |
| MLYS | Mineralys Therapeutics Inc. | 3,127,933 | $49,672 | 12.8% | $14.62 | -21.3% | Common Stock | 603170101 |
| ZBIO | Zenas BioPharma, Inc | 4,911,539 | $38,801 | 10.0% | $17.98 | -56.5% | Common Stock | 98937L105 |
| CRSP | CRISPR Therapeutics AG | 1,048,951 | $35,696 | 9.2% | $71.59 | -40.8% | Common Shares | H17182108 |
| DSGN | Design Therapeutics, Inc. | 6,526,476 | $25,192 | 6.5% | $16.67 | -71.4% | Common Stock | 25056L103 |
| ALMS | Alumis Inc. | 1,959,896 | $12,034 | 3.1% | $13.30 | -56.3% | Common Stock | 022307102 |
| OCS | Oculis Holding AG | 322,500 | $6,137 | 1.6% | $20.50 | 0.0% | Ordinary Shares | H5870P102 |
| NKTX | Nkarta, Inc. | 3,333,333 | $6,133 | 1.6% | $11.49 | -82.2% | Common Stock | 65487U108 |
| ORKA | Oruka Therapeutics, Inc | 430,330 | $4,415 | 1.1% | $33.46 | -62.7% | Common Stock | 687604108 |
| KALA | KALA Bio, Inc. | 598,940 | $3,432 | 0.9% | $6.53 | +15.9% | Common Stock | 483119202 |
| ENGN | enGene Holdings Inc. | 747,750 | $3,350 | 0.9% | $11.04 | -43.8% | Common Shares | 29286M105 |